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The effects of endocrine disrupting chemicals (EDCs) on the development of sexually 
dimorphic characteristics in vertebrates have been studied extensively for over sixty years. 
Throughout this time, studies have focused mainly on the disrupted steroidogenesis and steroid 
signaling pathways. Often, only freely suspended plasma steroids were reported, despite the fact 
that a large portion of plasma steroids are bound to circulating steroid transport proteins. When 
bound to transport proteins, steroids have reduced binding to steroid nuclear and membrane 
receptors and increased binding to transport protein receptors. Thus, steroid transport proteins 
regulate steroid activity. Sexually dimorphic characteristics of tissues require specific 
concentrations and milieus of steroids during development and disruption of these steroid milieus 
leads to abnormal differentiation. Therefore, it is likely that the developing organism also 
requires specific free and bound ratios depending on the sex. However, few studies have 
addressed the effects of EDCs on sexual dimorphism of steroid transport proteins and steroid 
fractions despite the impact that transport proteins have on steroid signaling, development, and 
physiology. To address this, I first summarize the current literature on the regulation of transport 
proteins, their interactions with steroid signaling, and how transport proteins are affected by 
 
 
environmental contaminates. These findings are culminated into a new model of steroid 
signaling that includes transport protein mediated pathways. Second, using HPLC-MS/MS, I 
show that a normal sexual dimorphism exists in free and bound steroid ratios for the steroids 
progesterone, corticosterone, testosterone, and 17β-estradiol. Additionally, I found a normal 
sexual dimorphism in the ratio of the bound precursor progesterone, to its potent metabolites, 
with females having higher progesterone to metabolite ratios than those in males. When exposed 
to the model EDC, Vinclozolin, sexual dimorphism of free and bound steroids was lost, with 
males and females responding to disruption in different ways. The disruption of plasma steroid 
ratios was found in the absence of changes to liver steroid transport protein concentrations. The 
results of this study show that steroid free and bound ratios as well as ratios of precursor to 
metabolite steroids can be altered by EDCs. This study clearly shows that future work in 
determining effects of EDC should also determine free and bound fractions of steroids to better 
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CHAPTER 1: EDCs ALTER STEROID TRANSPORT PROTEINS 
 
Introduction 
Since Berthold’s seminal work in the 1800s (Tata, 2005), the evolution of the field of 
endocrinology has been fueled by great minds and has led to great advancement in understanding 
disease prevention and treatment (Medvei, 1993). However, we face a crisis in the form of 
ubiquitous environmental pollutants, called endocrine disrupting chemicals (EDCs) (Gore et al., 
2015), that disrupt endocrine function and especially jeopardize embryonic development of 
humans and wildlife. The previous work of endocrinologists has described how environmental 
contaminants can affect steroidogenesis, steroid receptor function, and mechanisms of hormone 
feedback (Diamanti-Kandarakis et al., 2009; Gore et al., 2015), however, these are not the only 
components regulating steroid action.  
For decades, we have known that circulating steroid transport proteins regulate the 
activity and permeability of steroids through cell membranes and that these proteins exist in 
across vertebrate taxa. More recent work has shown that some cells have receptors that can bind 
hormone bound steroid transport proteins and induce intracellular effects. There is a paucity of 
studies that determine the mechanisms through which EDCs can alter steroid transport protein 
concentrations and their receptor functions. This deficit in our understanding of how EDCs affect 
steroid binding protein synthesis and function is an important gap in our understanding of the 
mechanisms through which EDCs alter health. The goals of this review are three-fold. First, we 
will synthesize the current understanding of steroid transport protein concentration and function 
during development. Second, we will summarize the current knowledge and identify critical gaps 
in our understanding of how steroid transport proteins are altered by EDCs. Finally, we will 




Steroids drive cellular differentiation, proliferation, and function in a tissue specific 
manner across the life span in all vertebrate taxa (Arnold, 2009). The correct timing and 
concentration of secreted steroid hormones are, therefore, essential for the normal development 
of tissue structure and function. Alterations to sex steroid signaling at critical times, especially 
during embryonic development, can lead to a diverse array of abnormalities in differentiation, 
growth, and metabolism (Gore et al., 2015). In fact, environmental contaminants known as EDCs 
can antagonize or agonize native steroid function and induce a variety of health problems. For 
example, the anti-androgenic fungicide Vinclozolin alters genitalia and testes development 
(Christiansen et al., 2008), and the xenoestrogen bisphenol A (BPA) used in production of some 
plastics induces altered mammary duct development (Munoz-de-Toro et al., 2005), endometrial 
growth (Markey et al., 2005), and prostate enlargement (Gupta, 2000).  
It is generally accepted that steroid signaling is dependent on steroid production, and 
nuclear receptor quantity and function (Mangelsdorf et al., 1995; Moras and Gronemeyer, 1998). 
Indeed, these mechanisms of steroid function have been the focus of much work detailing the 
effects of endocrine disrupting pollutants (Bergman et al., 2013). We know, for example, that the 
EDC atrazine can upregulate aromatase and increase conversion of androgens to estrogens 
(Sanderson et al., 2002; Sanderson et al., 2000), resulting in disrupted reproductive development 
(Hayes et al., 2002). Alternatively, vinclozolin exposure antagonizes the androgen receptor 
blocking its downstream effects (Kelce et al., 1997; Kelce et al., 1994), and during development 
decreases androgen receptor quantities (Amato et al., in revision). 
Although these well-known and thoroughly studied mechanisms are important, steroid 
transport proteins and their cognate receptors play critical roles in endocrine regulation and 




disrupting chemicals (EDCs) can alter steroid transport protein concentrations and their receptor 
functions.  
Normal circulating sex hormone availability is regulated by steroid transport proteins. For 
example, in the fetus Alpha-1-fetoprotein (AFP), Sex Hormone Binding Globulin (SHBG), 
Albumin (ALB), and Corticosteroid Binding Globulin (CBG) are serum steroid transport 
proteins produced by the liver, that bind circulating steroids with high affinity in developing 
male and female organisms across vertebrate taxa (Abelev, 1971; Keisler et al., 1995). The 
existence of steroid proteins, their high affinity to circulating steroids, abundance during 
embryonic development, and importance for maintaining adult homeostasis has been known for 
decades (Abelev et al., 1963). Steroids bound to transport proteins are less lipophilic and have 
reduced permeability into cell membranes. This change in permeability has a profound effect on 
the activity of the cognate steroid as entry of steroids, through the plasma membrane, allows 
steroids to bind intracellular nuclear receptors. As seen in (Fig 1A) bound and activated steroid 
receptors can then enter the nucleus and bind to a specific sequence (hormone response elements 
(HRE) of the promoter that modulates transcription of a number of downstream factors important 
for sexual and metabolic development (Mangelsdorf et al., 1995). 
Steroids in complex with circulating transport proteins are sequestered into the blood, 
where they form a circulating pool or “buffer” of inactive steroids that are more resistant to 
catabolism (Vermeulen et al., 1969). In this form they can be accessed as cellular needs arises 
and can be easily transported in plasma to distal target tissues. This buffer system is described as 
the “free hormone transport hypothesis” (Mendel, 1989). For instance, studies of glucocorticoids 
in sparrows have shown there are no seasonal changes in free plasma cortisol levels in response 




breeding season. This was due to the fact that, CBG concentration proportionately varied with 
the total cortisol levels as the animals were handled, resulting in increased total cortisol, but no 
net change in free cortisol (Breuner and Orchinik, 2002). Stress (due to handling) during the 
breeding season leads to larger increases the pool of circulating (total) cortisol relative to the 
nonbreeding season without changing concentrations of free presumable active hormone.   
In addition to promoting protection from degradation and transport to distant tissues, 
steroid-bound transport proteins can play a role in steroid function within target cells. Ligand 
complexed transport proteins have been shown to bind to specific membrane receptors on some 
steroid target cells (Hryb et al., 1990). When bound, these receptors elicit intracellular responses, 
via cyclic adenosine monophosphate (cAMP) activation of protein kinase A (PKA), that 
influence intracellular steroid function (Dagar and Bhattacharjee, 2015). This mechanism works 
directly via PKA or by facilitating steroid-nuclear receptor complex aggregation in the cytoplasm 
and/or nuclear receptor complex binding to an HRE (Heinlein and Chang, 2002; O'Malley et al., 
1995; Rosner et al., 1999). For example, binding of 17β-estradiol-SHBG complex to the SHBG 
membrane receptor activates the “fast” cAMP-PKA pathway, and increases secretion of prostate 
specific antigen in human prostate explants, a model steroid dependent process (Nakhla et al., 
1997). Prostate specific antigen secretion via the estradiol-SHBG-receptor complex was 
unaffected by estrogen receptor (ER) antagonists, while a PKA antagonism reduced prostate 
specific antigen (Rosner et al., 1999). Androgen-SHBG- receptor complex binding also induces 
cAMP/PKA changes and enhances androgen dependent responses of bound androgen nuclear 
receptor (AR) via phosphorylation of transcription factors (Heinlein and Chang, 2002). Overall, 
membrane receptors for AFP (Terentiev and Moldogazieva, 2013), SHBG (Heinlein and Chang, 




depending on the complexed steroid, may agonize or antagonize intracellular steroid signaling 
(Esteban et al., 1991; Fortunati et al., 1996; Rosner et al., 1999; Villacampa et al., 1984). The 
fact that transport proteins have cellular receptors that alter cellular physiology when bound by 
steroid-transport protein complexes illustrates that both free and bound hormone fractions play 
important roles in endocrine system function, and that they could be targets of endocrine 
disruption.  
Synthetic chemicals alter endocrine system function during development, and can lead to 
a variety of disorders at birth and later in life (Bergman et al., 2013). Such EDCs are widely 
produced and used, leaving populations of humans and wildlife exposed to detrimental 
alterations of hormone dependent development. EDCs can affect hormone function during 
steroid biosynthesis, metabolism, and receptor binding, often affecting multiple systems 
simultaneously (Diamanti-Kandarakis et al., 2009). However, the effects of EDCs on steroid 
transport proteins has been sparsely studied and currently presents a major gap in understanding 
the effects of EDCs on human and wildlife development, endocrine function, and health. Steroid 
transport proteins could be susceptible to alterations caused by EDC-induced changes in 
transport protein synthesis, and/or binding capacity (amount of ligand bound by given a 
concentration of protein) via competitive inhibition or allosteric modulation.  
AFP 
AFP is a fetal and neonatal serum binding glycoprotein found across diverse vertebrate 
taxa (Mizejewski, 2004) that binds circulating estrogens with high affinity (ka~0.8x10^8 M-1) 
(Savu et al., 1981) and several other circulating molecules at lower affinity such as bilirubin, fatty 
acids, retinoids, steroids, heavy metals, dyes, flavonoids, phytoestrogens, dioxins, xenoestrogens, 




Notably, AFP has very low affinity for testosterone (Swartz and Soloff, 1974). It is worth noting 
that some studies specific to humans, show negligible binding to estrogens, while others show 
evidence of conditional binding where high concentrations of 17β-estradiol or pretreatment with 
estrogen metabolites increased 17β-estradiol-AFP complexing. The contexts under which AFP 
binds to estrogens needs to be studied in more detail. High estrogen environments are common in 
certain cancers. (Swartz and Soloff, 1974; Uriel et al., 1975; Vakharia and Mizejewski, 2000), so 
AFP may play an especially important role in these cases.  
The ontogeny of AFP is best studied in mammals where it is present and functional 
throughout fetal sexual differentiation and neonatal periods. It is secreted primarily from visceral 
yolk sac and liver hepatocytes during mammalian fetal development (Andrews et al., 1982b; 
Janzen et al., 1982; Tilghman and Belayew, 1982) with the earliest recorded fetal mRNA 
expression in mice was found at embryonic day 9.5 (E9.5) (Gualdi et al., 1996) and by E26 days 
in humans. These dates coincide with development of primitive hepatocytes in the hepatic bud for 
their respective species (Jones et al., 2001). The highest concentrations of AFP are produced during 
mid-late fetal development with trace amounts of protein produced postnatally in humans 
(Ruoslahti et al., 1974) and rodents (Sell et al., 1974). AFP is the most dominant transport protein 
produced in the mammalian fetus and one of the most highly expressed proteins overall (Andrews 
et al., 1982a). The binding of AFP to estradiol during development protects the fetus from 
inappropriate exposure to maternal estrogens (De Mees et al., 2006) and possibly environmental 
estrogens (Mizejewski, 1995). Studies in rats have shown that it is necessary embryonically for 
the development of normal reproductive physiology and behavior (Bakker et al., 2006; Gabant et 
al., 2002; McEwen et al., 1975). For example, afp-null female rats are anovulatory (Gabant et al., 




(Bakker et al., 2006), resulting in infertility. As its name implies, it is absent in healthy adults, and 
is only detectable in some estrogen receptor related breast and liver cancers (Sell et al., 1976; Sell 
et al., 1974) as well as some germ line cancers (Ruoslahti et al., 1974). 
Normally, AFP is expressed in dividing hepatocytes in the developing fetus and expression 
slows as cells leave the proliferative state (Sell et al., 1974). Estrogen signaling plays a critical role 
in driving hepatocyte proliferation (Ciana et al., 2001) and liver growth (Uebi et al., 2015). For 
example, male rat livers treated with 17β-estradiol had increased liver proliferation and estrogen 
receptor alpha (ERα) protein expression (Francavilla et al., 1984), while livers exposed to 
tamoxifen, an ERα antagonist, slowed hepatocyte proliferation (Francavilla et al., 1989). 
Estrogens, then likely indirectly increase AFP via its proliferative actions. Indeed, it has been 
shown that estradiol or estriol treatment increases hepatocyte proliferation and serum AFP in a 
liver regeneration study using rats as a model (Alvaro et al., 2000). Though additional work is 
required to confirm that these findings also occur in the fetus, it can be surmised that estrogen and 
thus estrogen mimicking EDCs could indirectly increase AFP production by increasing the 
proliferative cells that produce it. 
However, diluted plasma from adult mice fed estradiol or control chow did not display 
high-affinity binding of estradiol. This lack of binding was interpreted as evidence that estradiol 
does not increase AFP levels in adults or neonates (Sheehan and Branham, 1981). Adults 
typically do not have high levels of AFP, and AFP is unlikely to be regulated by estrogens in this 
life stage, as estrogens cycle in the adult female drastically throughout the reproductive cycle, 
but AFP levels do not (they remain low). In addition, the use of binding capacity as an index of 
AFP concentrations is indirect. In contrast to adults, neonatal rats have high AFP levels (up to 4 




mice binding capacities, the dissociation constants did not change with estradiol treatment in 
neonatal rats, and this lack of change was, again, interpreted as a failure of estradiol to alter AFP 
levels. Although AFP production still occurs in neonates, it is known to be in decline at this 
stage. The role of AFP to protect the fetus from inappropriate estradiol exposure changes at birth 
as the brain requires estradiol to undergo sexual differentiation (McCarthy, 2008). Therefore, the 
neonatal stage might be the physiological window within which estradiol regulation of AFP 
production is being programed to no longer occur. Currently, influence of endogenous estradiol 
on fetal hepatocyte proliferation/growth and subsequent production of AFP during the 
appropriate developmental time window when AFP production is greatest is still unknown and 
should be formally evaluated.  
AFP and Endocrine Disruption 
There is a staggering number of known estrogenic compounds currently produced or still 
prevalent in soil (Xu et al., 2008) and water ways (Kuch and Ballschmiter, 2001), and this 
number grows as more commercial and industrial chemicals are manufactured. A few studies 
have investigated the effects of xenoestrogens on AFP production and function. For example, 
embryoid bodies formed in culture by human embryonic stem cells exhibited an increase in AFP 
mRNA expression when exposed to estradiol, the estrogen receptor modulator raloxifene, and 
endocrine disrupting chemical bisphenol A (Kim et al., 2012).  
In fish, the known EDCs, diethylstilbestrol (pharmaceutical estrogen (Giusti et al., 1995)) 
and 4-nonylphenoxyacetic acid (commercial/industrial estrogen, (Routledge and Sumpter, 1996)) 
showed significant competition with estradiol in binding to AFP, but only at concentrations 
about 100-fold greater than estradiol (Milligan et al., 1998). Therefore, in high concentrations, 




such as the prenatal female mouse brain (McCarthy, 2008), which would further exacerbate the 
direct effects of the EDCs. Alternatively, in lower concentrations, EDCs may not be effectively 
bound to AFP, and thus can freely circulate and enter sensitive tissues. Taken together, there are 
a number of environmentally available chemicals that might change AFP production and 
binding, particularly synthetic estrogen contaminants in waterways (Baronti et al., 2000). Future 
studies of estrogen and estrogen mimics should include AFP quantification and free/bound 
steroid fractions in their studies.  
SHBG 
SHBG is 50-70 kDa gylocoprotein, that binds sex steroids, primarily dihydrotestosterone, 
testosterone, and estradiol at high affinities. SHBG is produced primarily in embryonic liver 
hepatocytes and secondarily in the yolk sacs of all studied vertebrate taxa except birds (Hammond, 
2011; Wingfield et al., 1984) its common occurrence in embryonic tissues, there are few studies 
that focus on how SHBG is regulated during fetal development. The work that has been conducted 
on the regulation of SHBG has focused on the adult life stage, showing evidence that SHBG is 
regulated by hepatic nuclear factor-4α (HNF-4α) (Jänne and Hammond, 1998), peroxisome 
proliferator activated receptor gamma (PPARƴ) (Selva and Hammond, 2009a), thyroid hormones 
(Miguel-Queralt and Hammond, 2008), and the sex steroids (androgens and estrogens) (Anderson, 
1974). Insulin may also have a potential role in SHBG regulation as increased insulin and insulin 
resistance have been strongly correlated with increased testosterone and SHGB in women, and 
with a weaker correlation in men (Haffner, 1996). 
Hepatic nuclear factor-4α (HNF-4α), a member of the liver produced hepatic nuclear factor 
receptor family (a subset of the nuclear receptor superfamily), has been identified as a key 




Winters et al., 2014). HNF-4α is highly conserved across taxa and drives transcription of genes 
necessary for many adult liver functions, including xenobiotic/toxicant metabolism as well as 
carbohydrate and lipid metabolism. Furthermore, HNF-4α is requisite in embryonic development 
to drive liver differentiation (Li et al., 2000), and to no surprise, genetic knock-out of this gene is 
lethal (Hayhurst et al., 2001). HNF-4α was shown to drive SHBG translation when it was 
introduced to a SHBG promoter-luciferase reporter gene construct (Jänne and Hammond, 1998).  
Conversely, SHBG translation is repressed by PPARƴ  (Selva and Hammond, 2009a), a 
member of the PPAR nuclear receptor family, that is associated with uptake of lipids and increased 
lipogenesis (Lee et al., 2003). PPARƴ has a response element on the Shbg promoter and binding 
of PPARƴ agonists showed repression of SHBG production, while PPARƴ antagonists showed 
stimulation of SHBG production in HepG2 cells lines (Selva and Hammond, 2009a).  
SHBG production has been shown to be positively correlated with thyroid hormones as 
shown with thyroid hormone treatment in cell lines (Mercier-Bodard et al., 1991; ROSNER et al., 
1984) and with thyroid pathologies (Anderson, 1974). Though a thyroid hormone response 
element is not found on the shbg promoter, thyroid hormones have been shown to indirectly drive 
SHBG mRNA and protein production by increasing HNF-4α production (Selva and Hammond, 
2009b). 
Estrogen increases hepatic SHBG production. For example in adult men administration of 
20 pg of ethinylestradiol per day for 5 weeks increased in SHBG, as did the synthetic 
antiandrogen clomiphene (Anderson, 1974). Furthermore, ERα was required to increase SHBG 
production in human hepatoma cell lines when treated with mitotane, a known andrenocorticoid 
steroidogenesis inhibitor that decrease renal androgen production (Nader et al., 2006). This 




and not driven by the increased testosterone as treatment with antiandrogens did not decrease 
SHBG concentration. In addition, ERα and β in hepatocarcinoma cells were found to down 
regulate PPARƴ (Lin et al., 2013), which is expected to increase expression of SHBG by 
reducing PPARƴ mediated HNF-α repression. Although this specific mechanism has not yet been 
directly tested, synthetic estrogens are known to strongly increase serum SHBG in vivo 
(Anderson, 1974) and estradiol and synthetic estrogens increased SHBG in vitro. 
The direct role of androgens in SHBG regulation is not well understood as there are only 
a handful of studies that have addressed this relationship and with mixed results. For instance, 
some male patients diagnosed with hyperandrogenism, characterized by high circulating 
testosterone levels, had lower SHBG, whereas others had higher levels (Toscano et al., 1992). 
This variation might be related to the underlying mechanisms driving the hyperandrogenism. 
There is some evidence, in women, that androgens inhibit SHBG (Anderson, 1974). For 
example, women treated with Danazol (synthetic androgen) had decreased plasma SHBG 
(Gershagen et al., 1984) and increased levels of free testosterone (Forbes et al., 1986) relative to 
untreated women. It is clear that more studies are necessary to clarify the direct effects of 
androgens on SHBG especially in pregnant women where developing fetuses are potentially 
affected by the mothers’ exposure to environmental and endogenous androgens.  
While direct mechanisms are lacking, there are several studies that draw indirect links 
between androgen and SHBG via interactions between immune and hormone signaling systems 
(Simó et al., 2015). It is well known in both humans and wildlife studies that androgens regulate 
activity of immune cells, with both pro- and anti-inflammatory properties (Cohn, 1979; Klein, 
2000; Olsen and Kovacs, 1996), which is reviewed in (Olsen and Kovacs, 1996). For instance, 




(TNF-α) (Ashcroft and Mills, 2002) and an inhibitory effect on the adipocytokine, adiponectin 
(Nishizawa et al., 2002). Suppression of TNF-α has been associated with increased levels of 
serum SHBG (Sattar et al., 2007; Simó et al., 2012), and increases in anti-inflammatory 
adiponectin have been correlated with higher levels of SHBG (Crawford et al., 2015; Simó et al., 
2015). Additionally, inhibition of adiponectin, which is involved in regulation of insulin 
resistance and fatty-acid oxidation (Yamauchi et al., 2002), by testosterone may indirectly reduce 
SHBG production by reducing HNF-α signaling (Crawford et al., 2015). However, to our 
knowledge, no direct application of a non-aromatizable androgen has been studied in the context 
of fetal hepatic and placental SHBG production. 
 
SHBG and Endocrine Disruption 
Given the known mechanisms of SHBG regulation shown with thyroid hormones, and 
estrogens, and the indirect effects of androgens, endocrine disruptors could change SHBG 
production and function. Direct studies of EDC-induced effects on SHBG are uncommon, but we 
know EDCs affect the hormones that are believed to regulate SHBG. Thyroid hormones drive 
production of SHBG (Selva and Hammond, 2009b) and SHBG could therefore be altered by 
chemicals that affect the regulation of thyroid signaling. There has been a tremendous body of 
work that implicates a number of contaminants as thyroid disruptors (most notably 
polychlorinated biphenyls, BPA, perchlorate, and dioxins) with large potentials for altered brain 
development (Zoeller and Crofton, 2000) and metabolism (Patrick, 2009). Thyroid disruption has 
been shown in a wide variety of taxa including mammals (Patrick, 2009), amphibians (Carr et 




Estrogens increase production of SHBG (Anderson, 1974). EDCs with estrogenic or 
antiestrogenic effects, therefore, have a significant potential for altering steroid transport proteins 
such as SHBG. Studies of oral contraceptives and menopause treatment utilizing ethinylestradiol 
(Pugeat et al., 2010) have shown increased SHBG. Conversely, cancer therapeutics like 
tamoxifen, which binds and antagonizes ER signaling (Shiau et al., 1998) in breast cancer cells 
(Van Kammen et al., 1975), also show increased SHBG, suggesting that disruption of SHBG is 
complex, and likely nonlinear. We know that estrogens have nonmonotonic dose response curves 
(Lagarde et al., 2015), so high and low estrogen signaling could lead to similar effects. This 
highlights a concern for endocrine disruption of SHBG, as synthetic estrogens from widely used 
pharmaceuticals (ethinylestradiol, esterified estrogens, etc), urinated estrogenic metabolites, and 
common commercial/industrial products (e.g BPA and bisphenol S) are prevalent in the human 
and natural environments (Laurenson et al., 2014; Peng et al., 2008), and low concentrations are 
physiologically relevant. 
Currently, there are no studies that directly address possible endocrine disruption of HNF-
4α (Lyche et al., 2011), but PPARƴ, has shown to be altered by many EDCs, with detailed review 
in (Casals-Casas et al., 2008) and (Desvergne et al., 2009). Alterations in these transcription factors 
likely alter SHBG production and contribute to steroid related diseases, but this hypothesis and its 
implications on human and wildlife health need to be evaluated in detail.  
Disruption of SHBG production likely alters steroid activity in exposed organisms, but 
EDC-induced alterations in SHBG binding ability could also be detrimental. Exploration of 
SHBG’s active site affinity for possible pharmaceutical applications found that the structure is also 
permissible to non-steroidal ligands (Avvakumov et al., 2010). As with the synthetic estrogens 




and some change the conformation of the protein to affect native steroid binding (Tollefson et al., 
2001) and binding capacity (Van Kammen et al., 1975). For example, organochlorines and heavy 
metals were shown in vitro to facilitate testosterone and inhibit estrogen binding to SHBG of Green 
Turtles (Chelonia mydas) (Ikonomopoulou et al., 2009), and phytoestrogens can affect the binding 
effectiveness of SHBG to natural ligands (Martin et al., 1995). Interestingly, one study showed 
several known EDCs, including the heavy commercialized BPA, were able to bind human SHBG, 
though with significantly lower affinity than testosterone and estrogen. The effects of such low-
level binding on physiology and health are unknown and should be investigated. The implications 
for this nonspecific binding have not been explored but might be complex and far reaching. For 
example, the SHBG membrane receptor is activated only when the SHBG-ligand complex binds 
to it (Hryb et al., 1990). This binding results in fast intracellular responses to alter intracellular 
steroid receptor responses (Rosner et al., 1999) and depicted in (Fig 1C) Direct binding of EDCs 
to SHBG that alter binding of SHBG to native ligands, could likely disrupt the SHBG receptor 
function, and induce mechanisms of endocrine disruption that have not been contemplated.  
SHBG synthesis, circulating concentration, and binding function are at clear risk of 
alteration due to environmental chemicals, and should be studied in more detail. Furthermore, 
given that the normal function of SHBG is to control circulating bound and free fractions of 
estrogens and androgens, sex hormone concentrations are relevant endpoints to evaluate when 
studying the effects of EDCs on SHBG physiology. Importantly, we also have much to learn about 
the role that SHBG plays in regulating fetal hormone concentrations, and how those hormones 
feedback to regulate fetal transport proteins. Without this basic research, we cannot fully evaluate 






Albumin is a 65-70 kDA, globular, and non-glycosolated transport protein produced in 
both the fetal and adult liver across mammalian taxa (Huntley et al., 1977; Lampreave et al., 1982; 
Liao et al., 1980; Sellem et al., 1984; van den Akker et al., 2008; Viani et al., 1991). Albumin 
binds several circulating lipophilic molecules such as steroids, retinoids, and fatty acids at low 
affinity, but relatively high binding capacity (the total amount of ligand bound to amount of 
albumin). Albumin is first detectable in the mouse on E15 and by 130 days of human fetal 
development (Dancis et al., 1957). Albumin production and secretion from liver hepatocytes 
increases in the mouse from E15 until post-birth where it replaces AFP as the most abundant 
mammalian serum transport protein. Currently, there are few studies that specifically address 
whether or not steroids regulate hepatic synthesis of albumin, however, albumin has been shown 
to be increased by glucocorticoid exposure in rat hepatocyte culture (Bancroft et al., 1969; Nawa 
et al., 1986) and repressed by estrogens in reptiles (Selcer and Palmer, 1995), amphibians (Riegel 
et al., 1986), and fish (Flouriot et al., 1998). 
As a high capacity binder of lipophilic molecules, disruption of album by EDCs could 
cause significant changes in the availability of endogenous steroid hormones. For instance, if 
albumin protein concentrations are increased or decreased or binding affinity to steroids is altered 
the amount of free native steroid (unbound) and steroid transport to target cells would be affected, 
potentially for all steroids. Alternatively, changes in albumin concentrations or structure could 
affect its binding to disruptive xenobiotics in the bloodstream and remove them from activity 
(Baker, 2002).  
 




Currently there are only a few studies that explore the effects of exogenous chemicals on 
albumin production or function. Some of these studies show that EDCs bind directly to albumin. 
For instance, the xenoestrogens alkylphenols 4-tert-octylphenol, 4-nonlphenol , and several 
polyphenols bind to albumin (Soares et al., 2007; Xie et al., 2013). Albumin has also been shown 
to bind to synthetic and naturally produced estrogens such as diethylstilbestrol (Savu et al., 1981; 
SHEEHAN and YOUNG, 1979) and the phytoestrogen genistein (Bian et al., 2004). Fewer studies 
have attempted to characterize changes in the conformation of albumin, though structural changes 
of albumin can be induced by perfluoroalkyl acids (Qin et al., 2010) and naphthols (Wu et al., 
2007), which can potentially alter the normal binding of albumin to native and external steroid 
molecules. Therefore, albumin can directly bind to an EDCs at its active site, and/or undergo 
conformational changes due to EDC binding at allosteric sites. Given its extreme abundance and 
critical role in endocrine regulation, more work should focus on determining how common EDCs 
affect albumin production, circulating concentrations, and binding capacity.  
 
CBG 
CBG, also referred to as transcortin, is a monomeric glycoprotein that is approximately 50-
60 kDa and produced in the fetal and adult liver in all studied vertebrate taxa including amphibians, 
reptiles, and birds and mammals. Generally, across taxa CBG has high affinity to corticosteroids, 
slightly lower to androgens, and a weak affinity to estrogens though the strength to a particular 
steroid class may change depending on the species (Malisch and Breuner, 2010). For example, 
CBG in birds, who lack the strong (Brien, 1981)androgen binding SHBG, has a higher affinity to 




CBG is known to bind Serum concentrations (0.002 – 0.378 µg/mL) and binding capacity 
(0.023 – 0.432 µg/mL at 4°) ranging across adult species (Seal and Doe, 1965). Blood CBG 
concentrations closely mimic blood corticosteroid levels through development, with large steady 
increases of both in the late fetal stages until a plateau at the end of the neonate period (Henning, 
1978) .CBG concentrations and binding capacities have been shown to be naturally dimorphic in 
some species such as the rat, with females having significantly higher concentrations (Van Baelen 
et al., 1977) and capacity to bind corticosterone than males (Gala and Westphal, 1965).  
Dimorphism in CBG was not seen in humans (Brien, 1981). Testosterone appears to be a key 
driver of CBG as gonadectomy eliminated with males having CBG levels near females, which was 
rescued to the lower normal male levels with testosterone treatment (Van Baelen et al., 1977). The 
binding capacity of CBG to corticosterone decreased when female rats were exposed to 17β-
estradiol and testosterone while males had increased levels. Both males and females showed 
decreased CBG capacity when exposed to progesterone (Gala and Westphal, 1965). CBG synthesis 
has been shown to be influenced by corticosteroids and estrogens (Rosner, 1990). For instance, 
corticosteroids were found to inhibit CGB protein concentrations while estrogens caused an 
increase (Feldman et al., 1979). Diseases that increase cortisol levels, such as Cushing’s syndrome 
and Addison’s disease, result in lower concentrations of CBG and lower binding capacity to 
corticosteroids. (Frairia et al., 1988). However, increases in circulating CBG occurred with 
treatment of estrogens in adult humans (Seal and Doe, 1962), and during pregnancy (Daughaday 
et al., 1959), when concentrations of endogenous estrogens are known to be naturally high.  
 




Evidence has shown that there are environmentally pervasive corticosteroids (Hinson and 
Raven, 2006), estrogens (Kuch and Ballschmiter, 2001), antiandrogens (Kelce et al., 1994), and 
progestins (Chatterjee et al., 2008) with that act as endocrine disruptors. As noted in the previous 
section, all the above classes of steroids can affect either CBG concentrations or binding capacity. 
As with the previous transport proteins, the direct effects of EDC exposure on CBG has been 
poorly investigated, though the few studies that follow do suggest CBG concentration and function 
can be affected by pharmaceuticals taken medically or unintentionally via water contamination. 
Humans treated with the synthetic corticosteroid, cortisone acetate, had increased CBG binding 
capacity (Schlechte and Hamilton, 1987). Treatment with exogenous glucocorticoids have been 
shown to increase production of CBG in rat liver (Feldman et al., 1979) and circulating levels in 
human plasma (Schlechte and Hamilton, 1987). However, the anticorticosteroid ketoconazole (and 
antiandrogenic EDC (Taxvig et al., 2008)) increased CBG concentrations in patients with 
Cushing’s syndrome (Frairia et al., 1988).  
Synthetic estrogens used in contraceptives increase the bound fraction of cortisol in plasma 
(Bulbrook and Hayward, 1969). Estrogens also affect the percent of CBG bound cortisol. As an 
example, when treated with the pharmaceutical estrogens, diethylstilbestrol and ethinyl estradiol, 
women with breast cancer and men with prostate cancer had increased bound cortisol in circulation 
relative to before treatment (Sandberg and Slaunwhite, 1959). CBG binding capacity is also 
increased by exposure to a mixture of synthetic estrogens (conjugated estrogens, mestranol, 
norgestrel, and norethindrone) (Moore et al., 1978). Interestingly, women taking oral 
contraceptives have increased CBG, and higher serum total cortisol after stress tests (Kuch and 
Ballschmiter, 2001), suggesting that pharmaceutical and EDC exposure could affect stress 




2009) and natural bodies of water (Waste, surface, ground, stream, river, and lake) (Liu et al., 
2011) putting human and animal populations dependent on the fresh water at risk of altering CBG. 
This is particularly important for aquatic species such as fish that have multiple modes of EDC 
exposure: osmoregulation and respiration through the gills, exposed food sources, and through egg 
yolk deposition (Mills and Chichester, 2005). Disruption to CBG represents a critical threat to 
stress and metabolic maintenance in all vertebrate taxa, as glucocorticoids, the chief ligand of 
CBG, represent a conserved response to stress in all of these organisms. Altered glucocorticoids 
levels have been shown to effect immunocompetence in mice (Malisch et al., 2009) and early nest 
abandonment in European starlings (Love et al., 2004), and overall parental care (Wingfield et al., 
1998). Effects of EDC induced alterations of CBG may be most crucial during the reproductive 
seasons where glucocorticoids have shown to fluctuate in many taxa of birds, reptiles, fishes, 
amphibians (Breuner and Orchinik, 2002; Romero, 2002), and mammals (Romero et al., 2008). 
 
Conclusion 
Over the past century we have advanced from identifying the sources of hormones and their 
chemical structure to understanding their conserved nature, evolution, feedback regulation, and 
that each one can induce a multiplicity of effects (Lösel and Wehling, 2003). Our first 100 years 
of studying hormones cumulated into our understanding that all free circulating steroid hormones 
cross the lipid membranes of cells and interact with nuclear receptors to induce their effects 
(Tata, 2005). In the late 20th century, however, a new mechanism of steroid action was 
introduced (Norman et al., 2004), and it is now well accepted that free steroid hormones can bind 
to steroid receptors at the cell membrane to induce much quicker non-genomic responses than 




steroid membrane receptor signaling have been developed to study auditory learning in fish 
(Remage-Healey and Bass, 2004) and birds (Remage-Healey et al., 2011). With more research it 
is likely that rapid, non-genomic signaling will be found in neural development of other taxa as 
well. 
This rich and important body of work was accomplished without deep consideration of 
the role that steroid transport proteins were playing. Most studies suggested that steroid 
hormones were only functional when they were liberated from their blood-solubilizing proteins 
(Mendel, 1989), and could bind to cell membrane receptors, or cross the cell membrane and bind 
to nuclear receptors. Therefore, transport proteins were believed to decrease the concentration of 
free and functioning steroid hormones available to affect cell physiology. Relatively recent work, 
however, has shown that transport binding proteins play more interesting roles in driving steroid 
hormone action. Researchers have found that bound steroids paly a direct role in cellular 
physiology as their binding proteins have cell membrane receptors that can illicit cellular 
responses when bound by the steroid hormone-binding protein-hormone complex (Heinlein and 
Chang, 2002; Leonhardt et al., 2003; Li et al., 2002; O'Malley et al., 1995; Rosner et al., 1991). 
The roots of the studies that investigate the effects of endocrine disruption on binding-
protein biology stretch back decades, some as early as the 1970s (Van Kammen et al., 1975; 
Williams et al., 1978). This work does show evidence of altered steroid transport protein synthesis, 
binding capacity and affinity, and altered circulating hormone concentrations across multiple taxa. 
Here, we suggest that the effects of EDCs on steroid transport proteins likely presents an important 
and drastically understudied form of endocrine disruption and requires increased study regardless 




Furthermore, the existence of steroid transport specific receptors suggests an additional 
pathway of steroid signaling that has received little attention. As the evidence presented in the 
review has shown, steroid signaling and its disruption is not limited to the “classic” genomic 
signaling pathway, or even membrane steroid receptors (Lösel and Wehling, 2003), but also 
transport protein receptors. All three signaling pathways have the potential to be disrupted. EDC 
exposure can agonize or antagonize intracellular steroid nuclear receptors directly altering how 
they bind to the HRE and changing transcription of steroid dependent transcripts (Fig 1.1A and 
1.1D). Steroid membrane receptors can also be agonized or antagonized by EDC binding, altering 
activation of Ca2+ channels and MAPK/ERK signaling and affecting both recruitment of 
transcription factors and direct phosphorylation of steroid nuclear receptors (Fig 1.1B and 11.E). 
Lastly, EDCs can alter the ability of steroid transport proteins to bind their ligands or their 
membrane bound receptors. This disruption can again be agonistic or antagonistic, resulting in 
changes to Ca2+ channels and cAMP mediated PKA activation. Changes to PKA cascades induced 
by hormone-transport protein complex binding to membrane receptors affect phosphorylation and 
recruitment of steroid nuclear receptor cofactors and downstream gene expression (Menazza and 
Murphy, 2016; Pietri et al., 2016) (Fig 1.1C and 1.1F). Here we argue that these mechanisms (Fig 
1.1A-C) of steroid function are not mutually exclusive but are integrated across cells, tissues, and 
body systems and that dysfunction in any of these mechanisms likely feedback to alter other 
aspects of the endocrine system. Therefore, each of these mechanisms must be considered as 
potential targets for endocrine disrupting chemicals. This model expands upon the brilliant work 
that endocrinologists have done since the field’s conception in the mid-1800s and provides a 
synthetic picture of steroid signaling and facilitates the generation of new hypotheses to test novel 




and human health we must fully characterize how these pervasive chemical pollutants affect 
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CHAPTER 2: FETAL STEROID FREE AND BOUND FRACTIONS ARE DIMORPHIC AND 




Sexually dimorphic tissue development and function requires tight regulation of steroid 
concentrations. Aberrant steroid signaling during critical windows of development, within which 
the fetus is especially sensitive to hormone signaling, results in a number of endocrine-related 
diseases at birth or that manifest in adulthood. It is well established that perturbations in ligand-
receptor binding and steroids concentrations can be detrimental especially to the fetus (Colborn 
et al., 1993). What is less well understood is the role steroid transport proteins serve to control 
proper signaling and mitigate improper signals (i.e. from environmental contaminants) (Uriel et 
al., 1972), and maintain normal dimorphism. Steroid transport proteins bind circulating steroids 
during critical stages of sexual differentiation and segregate steroids into two distinct and 
functionally different fractions: bound and unbound steroids which interact with cells in 
fundamentally different ways. 
 
Steroid transport proteins regulate sex hormone availability and diffusion through the lipid 
bilayer. In the fetus, Alpha-1-fetoprotein (AFP), Sex Hormone Binding Globulin (SHBG), 
Albumin (ALB), and Corticosteroid Binding Globulin (CBG) are plasma transport proteins 
produced by the liver, that bind circulating steroids with high affinity in developing male and 





transport proteins are less lipophilic and have reduced permeability through cell membranes and 
binding to nuclear receptors is therefore reduced. Consequently, steroids that are bound to 
circulating binding proteins are sequestered in the blood, where they form a circulating reserve 
or “buffer” of steroids that are more resistant to catabolism (Vermeulen et al., 1969), and can be 
easily transported in plasma to distal target tissues (Mendel, 1992), so they can be accessed as 
cellular needs arises.  
 
Classically, the bound fraction of steroids has been considered “inactive” in its ability to drive 
steroid signaling in the classic steroid genomic signaling pathway, where only the fraction of 
steroids that is unbound to transport proteins are “active” and can permeate the lipophilic cell 
membrane to activate gene transcription. This long-standing theory is known as the “free 
hormone transport hypothesis” (Mendel, 1989). However, in addition to protecting steroids from 
degradation and aiding in transport to distant target tissues, recent evidence shows that binding 
proteins bound to steroid can play a role in non-genomic steroid signaling. Indeed, steroid-
complexed binding proteins have been shown to bind to binding protein specific membrane 
receptors on diverse target cells such as human endometrial tissue (Avvakumov et al., 1986), 
prostate (Hryb et al., 1986), hippocampus (Herbert et al., 2005) breast cell line (Porto et al., 
1992b), as well as rat testes (Porto et al., 1992a), and hippocampal cell lines (Caldwell et al., 
2000). Steroid bound transport proteins bound to their receptors activate phosphorylation 
cascades that modify intracellular steroid function and the binding of steroid nuclear receptors to 
their promoters (Porto et al., 1992a). Thus, bound steroids, in addition to free, play an important 





We know that synthetic endocrine disrupting chemicals (EDCs) can affect all aspects of hormone 
function: including steroid biosynthesis, metabolism, receptor binding, or often affecting 
multiple systems simultaneously (Diamanti-Kandarakis et al., 2009). However, the effects of 
EDCs on steroid transport protein concentrations, and their interactions with their cognate 
steroids have been sparsely studied. The vast majority of EDC studies do not distinguish free or 
bound fractions of steroids, generally reporting only on free or total concentrations. Limited data 
suggests that EDCs can affect transport protein synthesis (Pugeat et al., 2010), and disrupt their 
natural binding capacity via competitive inhibition at high concentrations (Milligan et al., 1998).  
These changes could affect free and bound steroid concentrations resulting in changes for both 
genomic and non-genomic steroid signaling. In adulthood, gonadal and adrenal steroids are 
known to bind receptors in the hypothalamus and pituitary in a negative feedback loop, reducing 
secretion of the gonadotropins and corticotropins (respectively) and thus limiting further 
secretion of gonadal and adrenal steroids. No evidence currently shows how changes in steroid 
transport proteins directly affects negative feedback, however it is likely that free steroids can 
bind to brain nuclear receptors whereas bound steroids cannot. Disruption of binding protein 
concentrations or binding of would lead to alterations of the free and bound fractions of steroids, 
which may affect the ratio of genomic to non-genomic signaling and have impacts on steroid 
feedback. Additionally, steroids exist as a part of the cholesterol metabolic pathway, where 
changes in the fractions of upstream precursor-molecules like progesterone, can alter available 
substrate for downstream steroids such as glucocorticoids and androgens or estrogens steroids.  
 
Ultimately, the lack of knowledge of how EDCs affect steroid transport proteins and their 




a major gap in understanding the sex-dependent risks EDCs pose to human and wildlife 
development, endocrine function, and health (Mogus and McCoy, 2018, in review). Here we test 
the hypothesis that exposure to the model EDC and antiandrogen, Vinclozolin, during sexual 
differentiation alters murine concentrations of free and bound fetal plasma progesterone, 
corticosterone, testosterone, and 17β-estradiol, and that these changes affect the ratios of 
precursor steroids to their metabolized products (e.g. Progesterone/Testosterone), and that the 
nature of the changes are sex dependent. Then we test the hypothesis that fetal mouse liver 
steroid binding protein concentrations (alpha-1-fetoprotein, albumin, and corticosteroid binding 
globulin) are altered by Vinclozolin and in a sex dependent way. 
 
Materials and Methods 
Animal Studies 
All studies were carried out under an approved protocol established by East Carolina University 
(ECU) Institutional Animal Care and Use Committee (AUP D-297 and AUP D-297a). Eight-
week-old CD-1 mice were purchased (Charles River Breeding Laboratories Raleigh, NC) and 
acclimated for at least 7 days to 70-72 F on a 12 h light-dark cycle with free access to food and 
water (Purina ISOCHOW).  
 
Vinclozolin Exposure 
CD-1 mice were time mated by placing males and virgin females together in the evening, and 
females were checked for vaginal plugs each subsequent morning. A vaginal plug indicated that 
a mating had occurred that night and the female was identified as embryonic day (E) 0.5 at noon 




(cat# 45705, Sigma-Aldrich, St. Louis, MO), dissolved in Tocopherol striped corn oil (cat# 
901415, Millipore, Burlington, MA), or Tocopherol striped corn oil alone (Solvent control) once 
a day from E 13.5-16.5. All doses were given between 11am- 1pm via gavage. This dosing 
regimen is known to induce endocrine disruption and induce hypospadias (feminized male 
genitalia) 100% of the time in mice (Amato and McCoy, 2016). Masculinization of the genitalia 




To determine steroid concentrations within fetal plasma, pregnant dams were dissected 1 hr. after 
their fourth and final treatment dose on day E16.5, and embryos were removed. Embryonic age 
was confirmed by Theiler stage criteria (Stage TS24) (Theiler, 2013). The carotid and thoracic 
arteries of each embryo was cut, and blood was collected using a heparinized 20-gauge x 
(0.9mmx25mm) needle (cat# 305175, BD, Franklin Lakes, NJ) attached to a 1cc syringe (cat# 
9625, BD, Franklin Lakes, NJ). The syringe tip was filed down and dulled to prevent puncture 
and to reduce clogging (de Lurdes Pinto et al., 2008). Collected blood was centrifuged for one 
minute without prior clotting, and plasma supernatant was collected via a pipetter. Plasma 
samples were immediately stored at -20˚C. The carcasses were dissected in cold 1x PBS (cat# 
BP665-1, Fischer Scientific, Fairlawn, NJ) and sex was determined based on gonad phenotype, 
which is not altered using this dosing regimen. Fetal livers were collected, weighed, and snap 
frozen in liquid nitrogen. Frozen livers were stored in a -80˚C freezer until processing for 
proteomics. Livers were transported over dry ice to the Center for Human and Health and 





Fetal Plasma Metabolomics 
Plasma sample preparation 
Plasma was thawed and pooled based on sex within each dam (n=5). Depending on volume 
collected, between 20-50µL and were transferred to 16x125mm borosilicate glass tubes (cat# 
47729-578, VWR, Radnor, PA) and then spiked with a 20µL of mixture of deuterated steroid 
standards, consisting of: corticosterone-D8 (0.25µg/mL; cat # Q3460-020, Steroloids Newport, 
RI), 17β-estradiol-D5 (0.5µg/mL; cat# E0950-000, Steroloids, Newport, RI ), progesterone-D9 
(0.005 µg/mL, cat# Q2600-014, Steroloids, Newport, RI)), and testosterone-D3 (2.5µg/mL, cat# 
T-046, Cerilliant, Round Rock, TX) diluted in Optima Grade Acetonitrile (cat# A955-1, Fischer 
Scientific, Fairbanks, NJ). A remaining volume of Optima Grade Water (cat# W6-1, Fischer 
Scientific, Fairlawn, NJ) was added to each sample to bring the total volume up to 500µL of 
solution. 
 
An external calibration curve was prepared using mixtures of non-deuterated standards of 
corticosterone (cat# C-117, Cerilliant, Round Rock, TX), 17β-estradiol (cat# E-060, Cerilliant, 
Round Rock, TX), progesterone (cat# P-069, Cerilliant, Round Rock, TX), and testosterone (cat# 
T-037, Cerilliant, Round Rock, TX). The non-deuterated steroids were mixed and serially diluted 
in Optima Grade Acetonitrile (cat# A955-1, Fischer Scientific, Fairbanks, NJ) to make a standard 
external calibration curve with the range: 0.0005, 0.005, 0.05, 0.5, and 5.0 µg/mL of steroid. 
Twenty µL of each mixed external steroid concentration was added to 480 µL of water in 
individual 16x125 mm borosilicate glass tubes. Solvent blank tubes were prepared by adding 500 





Unbound steroid extractions  
To extract unbound steroids, calibration curves, and blanks three mL of methyl-tert-butyl-ether 
(cat# 306975, Fischer Scientific, Fairbanks, NJ) was added to each tube. Samples equilibrated 
for one min, vortexed at 700rpm for five minutes, settled for two min, and vortexed for two min. 
With organic and aqueous phases clearly separated, sample tubes were placed in a methanol 
(cat# 34860, Fischer Scientific, Fairlawn, NJ)/dry ice slurry until the aqueous phase was frozen. 
The organic phase was poured off and collected in 12x75mm borosilicate glass collection tubes 
(cat# 14-961-26, Fischer Scientific, Fairlawn, NJ), and dried via a constant stream of N2 gas at 
room temp. The aqueous phase was thawed, and the extraction process was repeated for a total of 
five extraction cycles, each time pouring off only the organic phase into the same 12x75mm 
collection tubes and drying with N2 gas. After the fifth extraction cycle, the 12x125mm aqueous 
phase tubes were stored in -20°C until use in the bound steroid extraction.  
 
Bound steroids extraction 
Bound steroids were extracted from the frozen aqueous phase generated in the procedure above 
using the same protocol but with the following additional steps. First, 16x125mm tubes with 
aqueous phase precipitate were spiked with an additional 20µL of deuterated standard mix. This 
was necessary as the first series of extractions removed all the spiked standards (Fig. 2.1). A new 
standard tube was added with 20µL of deuterated standard spiked into 480µL of water was 
added as a reference that that we could measure the amount of residual standard left from the 
free steroid extraction. A new external standard series was also added. To release the bound 




proteins and release bound steroid (Grabski and Novagen, 2001). All tubes were then extracted 
as in the above unbound steroid extraction. 
 
Extracted steroid resuspension 
Dried organic extract from bound and unbound extractions (in 12x75mm) tubes were 
resuspended for liquid chromatography/mass spectrometry (LCMS) analysis in 65µL of 70% 
optima grade acetonitrile. The solutions were then vortexed for five minutes to collect residual 
extract on the sides of the tubes, and centrifuged for five minutes at 10,000rpm and 4˚C. The 
solutions were then transferred to autosampler vials and stored at -20˚C until LCMS analysis. 
 
Liquid chromatography/mass spectrometry 
Extracted steroids were identified using a Sciex Exion LC 100 Liquid chromatography system 
coupled with Sciex API 3200 triple quadrupole mass spectrometer. A Phenomenex Kinetex 
2.6µm C18 100 Å, 100x3 mm column (cat# 00D-4462-Y0, Phenomenex, Torrance, CA, USA) 
was used for positive and negative ionization analysis.  
 
Positive ionization 
Testosterone, progesterone, corticosterone, and two estradiol transitions were optimized using 
positive electrospray ionization. The LC method for these targets included the following mobile 
phases: Solvent A = 5% acetonitrile with 0.1% formic acid (cat# F0507, Fischer Scientific, 
Fairlawn, NJ) and Solvent B = 100% acetonitrile. LC gradient consisted of 1min 100% A/0% B, 
1-7min increased to 5% A/95% B, 7-9min 5% A/95% B, 9-10min decreased to 100% A/0% B, 




instrument parameters for positive mode are shown in Table 2.1. Transitions for steroids are 
listed in Table 2.2.  
 
LC-MS/MS Analysis 
Plasma steroid molecule peaks detected by LC-MSMS were analyzed using Analyst software 
version 1.6.3. Peak integrations were analyzed with Mutliquant version 3.0.3 using external 
standard curves to determine sample concentrations. Internal (deuterated) standards were used to 
confirm observed concentration trends and values of the external curves.   
 
Statistical Analysis 
To control for technical differences between runs, plasma steroids were extracted and analyzed 
via LC-MS/MS as blocks, with a block consisting of a complete experimental replicate (one 
representative sample of each treatment group). Steroid concentrations were log transformed to 
contend for zero inflation (many concentrations were close to 0.0µg/mL) and analyzed with 
normal distributions using linear mixed models with dam as a random effect. Plasma steroid 
concentrations have inherent variation as their secretion is pulsatile and fluctuates through time 
and some biologically important changes may not be identified as statistically significant if 
threshold p-value is less than 5% (P<0.05). To contend for potentially important trends, we 
define significant statistical difference between groups as (P<0.05) and marginally significant 
statistical difference as (P<0.10). 
 
Fetal Liver Proteomics 




Fetal livers were thawed and 25mg collected from liver samples. Excess blood was washed off 
liver with cold PBS. The 25mg samples were made by independently cutting the livers into 
several small pieces and randomly selecting up to 25mg of liver pieces to assure random 
sampling of the liver tissue. 2 volumes of cold lysis buffer, made of 1% sodium deoxycholate 
surfactant (SDC, Cat# S3014, Sigma-Aldrich, St. Louis, MO) /50mM ammonium bicarbonate 
(Cat# 09830, Sigma-Aldrich, St. Louis, MO), were added to each 25mg of liver sample. Liver 
solutions were fully homogenized with a probe blender for five to ten seconds (depending on 
sample) and then sonicated for 20 seconds in two intervals with one minute in an ice bath 
between intervals. Sample solutions were then centrifuged at 16,000xg for ten minutes at 4°C. 
Supernatant was removed via pipetter and pellets saved for proteomic analysis preparation.  
SDS-PAGE and BCA assays were conducted to access quality of protein yield.  
 
50mM ammonium bicarbonate with 1% SDC was added to each pellet. Then MDL-
Dithiothreitol (DTT, Cat# 43815, Sigma-Aldrich, St. Louis, MO) was added to each pellet 
solution to reach a concentration of 5mM and incubated for 60°C for 30 minutes. 15mM 
Iodoacetamide (IAM, Cat# I6125, Sigma-Aldrich, St. Louis, MO) was added to each sample 
solution and then incubated for 20 minutes in the dark (IAM is light sensitive). Protein clean-up 
preparation was completed using FASP (Filter Aided Sample Preparation) (Wisniewski et al., 
2009). Vivacon 500 30kD spin filters (Cat# 50-311-816; Fischer Scientific, Fairlawn, NJ) were 
prepped by adding 20µL of 1% SDC to passivate the spin filters. Sample solutions were then 
transferred to the spin filters, avoiding the protein pellet, and then centrifuged at 14,000xg for 15 
minutes to dry the pellet. Then 200µL of 8M Urea (Cat# U5378, Sigma-Aldrich, St. Louis, MO) 




repeated the process a second time with fresh urea. Next, 200µL of 50mM ammonium 
bicarbonate (no urea) was added to each sample and then centrifuged at 14,000xg for 15 minutes 
to, repeating the process a second time.  
 
70µL solution of trypsin (Cat# V5111, Promega, Madison,WI) with 0.01% acetic acid was added 
to each sample in 50mM ammonium bicarbonate buffer. The solutions were digested for four 
hours at 37°C.   Sample solutions were acidified (to pH of 2) with 4µL of 6M hydrochloric acid 
and then centrifuged at 12,000xg for 15 minutes. Filters were then washed with 20–30 µL 
(enough o reach 100µL total volume) and centrifuged at 12,000xg for ten minutes or until dry. 
Samples were kept in their microcentrifuge tubes at -20°C. 
 
Liquid chromatography/mass spectrometry 
Cleaned and digested protein peptides were identified using liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Peptides (1µg) were loaded onto a 35cm C18 column (reverse phase 
ReproSilPur 120C-18-AQ 3µm particles, (Cat# H354, New Objective, Woburn, MA) and eluted 
using a 240-minute gradient with an Easy-nLC 1000 coupled to a Q-Exactive Plus orbitrap mass 
spectrometer. After a 2µL volume injection, sample peptide separation was achieved on the LC 
using a gradient of mobile phase A (98% water, 2% acetonitrile, and 0.1% formic acid) and 
mobile phase B (100% acetonitrile, 0.1% formic acid). The 270min method included an LC 
gradient with a linear increase from 2% B to 40% B across minutes 2 to 242.  This was followed 
by an increase and wash at 80% B from 242–254 minutes, followed by equilibration of the 





Tandem mass spectrometry was processed in top 12 data-dependent acquisition mode. MS1 and 
MS2 scans were performed at a resolving power of 70k and 17.5k. A dynamic exclusion window 
of 20 seconds was used to avoid redundant interrogation of abundant species. Bovine serum 
albumin was run on column after every three injections to confirm LC-MS/MS reproducibility.   
 
Raw data were processed using MaxQuant linked to the mouse Uniprot protein sequence 
database. Multiple comparisons in large data sets such as the one used here have innate false 
discovery errors. To contend for this, the threshold false discovery rate (FDR) was set at 1% for 
both the peptide and protein levels. The “match between runs” program feature was used to 
increase peptide identification via molecular mass and retention time across runs.   
 
Significant proteins by Fisher's exact test (p<0.05) were then verified by integrating the intensity 
under the extracted ion chromatogram from a single unique peptide for each protein across all 
runs. A two-sample t-test (p<0.05) based on integrated peak intensities discovered differences in 
145 proteins for control versus vinclozolin males, 139 proteins for control versus Vinclozolin 
females, and 167 proteins for corn oil males versus females, and 104 proteins for Vinclozolin 
males versus females. Proteins were then quantified using the label-free MaxLFQ (Cox et al., 
2014) program in MaxQuant. Protein group filtering, transformation, imputation, and T-test were 
analyzed using Perseus (Tyanova et al., 2016).  
 
The differential proteins were validated using a triple quadrupole mass spectrometer operating in 
selected reaction monitoring (SRM) mode. Comparison of peptide abundance across treatments 




significant findings. Relative protein quantitation was performed using label free methods 
(integration of area under the curve) using Skyline and the MSstats package. 
 
Results 
Vinclozolin eliminates sexual dimorphism  
Progesterone 
For free progesterone concentrations no significant effects were found for the for the main 
effects of sex (χ2 = 0.0006, df = 5, p = 0.9798), or treatment (χ2 = 0.3433, df = 4, p = 0.5579), or 
for their interaction (χ2 = 1.1048, df = 6, p = 0.2932). For bound progesterone, no significant 
effects were found for the main effects of sex (χ2 =2.2196, df = 5, p = 0.1363) or treatment (χ2 
=0.2885, df = 4, p = 0.5912), however, a significant interaction between sex and treatment was 
identified (Fig. 2.2A, χ2 =5.1121, df = 6, p=0.02376). Bound progesterone was found to be 
dimorphic between the sexes and was 1.54 times higher in female (x = 9.6406) relative to male 
(x = 6.2780) corn oil controls. Vinclozolin treated animals showed a reduced dimorphism in 
bound progesterone (effect size = -33.00% difference). Vinclozolin treatment slightly decreased 
bound progesterone in females (x = 9.2336) and increased bound progesterone in males (x = 
8.9844) for a 1.03 difference between sexes.  However, no significant effects were found for the 
for the main effects of sex (χ2 = 0.1998, df = 5, p = 0.6549), or treatment (χ2 = 0.3554, df = 4, p 
= 0.5511), or for their interaction (χ2 = 2.3119, df = 6, p = 0.1284) for total progesterone 
concentrations. 
 
Significant effects were found for the main effect of sex (Fig. 2.2B, χ2 =4.7638, df = 5, effect 




df = 4, p = 0.7154) for the ratio free to bound progesterone. However, a significant interaction 
between sex and treatment was identified for the ratio of free to bound progesterone (Fig. 2.2B, 
χ2 =10.168, df = 6, p=0.001429). Corn oil control females and males showed a dimorphism in 
their free to bound ratio, with females (x = -1.9032) having a lower ratio of free relative to bound 
progesterone than males (x = 3.2924). Vinclozolin treatment increased the free/bound ratios in 
females (x = 0.0579, effect size = 3887% increase) and reduced the ratio in males (x = -0.0316, 
effects size 96.0% decrease), decreasing the dimorphism. 
 
17β-estradiol 
For free 17β-estradiol, no significant effects were found for the main effects of sex (χ2=1.8505, 
df=5, p=0.1737), or treatment (χ2=0.1488, df=4, p=0.6996), or the interaction between sex and 
treatment (χ2=0.2507, df=6, p=0.6166) for free 17β-estradiol. No significant effects were found 
for the main effects of sex (χ2=0.5713, df=5, p=0.4497), or treatment (χ2=0.1281, df=4, 
p=0.7205), or their interaction (χ2=2.4537, df=6, p=0.1172) for bound 17β-estradiol. No 
significant effects were found for the main effects of sex (χ2=1.8926, df=5, p=0.1689), or 
treatment (χ2=0.1540, df=5, p=0.6947), or between the interaction of sex and treatment 
(χ2=1.8464, df=6, p=0.1742) for total 17β-estradiol. 
 
No significant effects were found for the main effect of sex (χ2=0.1554, df=5, p=0.6934) or 
treatment (χ2=0.4893, df=4, p=0.4842) for the free-to-bound ratio of 17β-estradiol. However, a 
significant interaction was detected between sex and treatment (Fig. 2.3, χ2 =7.0586, df = 6, 
p=0.007889) for the free to bound ratio of 17β-estradiol. Corn oil control females and males 




having a less free relative bound 17β-estradiol than males (1.4600). Vinclozolin treatment 
increased the free/bound ratios in females (x = 0.3686, effect size = 329.99% increase) and 




There were no significant effects observed for the main effects of sex (χ2=0.6766, df =5, 
p=0.4108) or treatment (χ2=0.0524, df= 4, p=0.8189) for free corticosterone. However, a 
marginally significant effect was found between the interaction of sex and treatment (χ2=3.4541, 
df=6, p=0.06309) for free corticosterone concentrations.  For bound corticosterone, a marginally 
significant effect was seen for the main effect of sex (χ2= 2.9998, df=5, p=0.08327), though not 
for treatment (χ2=1.8187, df=6, p=0.1775).  No significant effect was found between the 
interaction of sex and treatment (χ2=0.1530, df=4, p=0.6956) for bound corticosterone. No 
significant difference was found between the main effect of sex (χ2=0.6708, df=5, p=0.4128), or 
treatment (χ2=0.0277, df=4, p=0.8678) for total corticosterone. A marginally significant effect 
was found between the interaction of sex and treatment (χ2=2.7876, df =6, p=0.0950) for total 
corticosterone. No significant effect was found for the main effect of sex (χ2=2.5555, df=5, 
p=0.1099), or treatment (χ2=2.3783, df=4, p=0.1230), or between the interaction of sex and 
treatment (χ2=0.0053, df=6, p=0.9422) for the ratio of free/bound corticosterone. 
 
Testosterone ratios unchanged by Vinclozolin exposure 
No significant effect was found for the main effects of sex (χ2=05404, df=5, p=0.4622), or 




df=6, p=0.3592) for free testosterone. No significant effect was found for the main effects of sex 
(χ2=0.0472, df=5, p=0.8279), or treatment (χ2=0.3100, df=5, p=0.577), or the interaction 
between sex and treatment (χ2=0.0041, df=6, p=0.9490) for bound testosterone. No significant 
effect was found for the main effects of sex (χ2=0.8957, df=5, p=0.3439), or treatment 
(χ2=0.0055, df=5, p=0.9409), or between the interaction of sex and treatment (χ2=0.9084, df=6, 
p=0.3405), for total testosterone. No significant effect was found for the main effects of sex 
(χ2=0.1291, df=5, p=0.7194), or treatment (χ2=0.0714, df=5, p=0.7892), or the interaction 
between sex and treatment (χ2=0.0134, df=6, p=0.9079) for the ratio of free/bound testosterone.  
 
Ratios of bound steroid precursor, Progesterone, to downstream targets lose sexual dimorphism 
when exposed to Vinclozolin. 
Progesterone / Testosterone 
No significant effect was found for the main effects of sex (χ2=0.0189, df=5, p=0.8907), or 
treatment (χ2=1.0234, df=4, p=0.3117), or the interaction between sex and treatment (χ2=1.4261, 
df=6, p=0.2324) for the ratio free progesterone to free testosterone. A significant effect was 
found for sex (Fig.3A, χ2=7.8258, df=5, p=0.0052) in bound progesterone to bound testosterone, 
but not for treatment (χ2=0.0.6227, df=4, p=0.4300). A significant interaction was detected 
between sex and treatment (Fig. 2.4A, χ2 =10.500, df = 6, p=0.0012) for the ratio of bound 
progesterone to bound testosterone. Corn oil control females and males showed a dimorphism in 
their ratio of bound progesterone to bound testosterone, with females (x = 1.4724) having a 
higher ratio of bound progesterone to bound testosterone than males (x = -2.4779). Vinclozolin 
treatment decreased the bound progesterone to bound testosterone ratios in females (x = 0.7497, 




308.04% increase), decreasing the dimorphism. No significant effect was found for sex 
(χ2=1.0416, df=5, p=0.3075), treatment (χ2=1.5549, df=4, p=0.2124) or the interaction between 
sex and treatment (χ2=1.068, df=6, p=0.2356) for the ratio of total progesterone to total 
testosterone.  
 
Progesterone / 17β-estradiol 
No significant effect was found for the main effects of sex (χ2=0.1473, df=5, p=0.7011), or 
treatment (χ2=1.5723, df=4, p=0.2099), or the interaction between sex and treatment (χ2=0.6267, 
df=6, p=0.4286) for the ratio free progesterone to free estradiol. A significant effect was found 
for the main effect of sex (Fig. 2.4B, χ2=0.6.8336, df=5, p=0.0089), but not treatment (χ2 
=2.2759, df = 4, p=0.1314) in bound progesterone to bound 17β-estradiol. A significant 
interaction was detected between sex and treatment (Fig. 2.4B, χ2 =8.5782, df = 6, p=0.0034) for 
the ratio of bound progesterone to bound 17β-estradiol. Corn oil control females and males 
showed a dimorphism in their ratio of bound progesterone to bound estradiol, with females (x = 
0.4344) having a higher ratio of bound progesterone to bound 17β-estradiol than males (-4.3784). 
Vinclozolin treatment decreased the progesterone to estradiol ratios in females (x = -0.8010, 
effect size = 164.84%) and increased the ratio in males (x = 0.3224, effect size = 9,314.04% 
increase), decreasing the dimorphism. 
 
No significant effect was found for the main effect of sex (χ2 =1.0416, df =5, p=0.3075) in total 
progesterone to total 17β-estradiol, but a significant effect was found for treatment (χ2 =3.3505, 
df = 4, p=0.0672) and for the interaction between sex and treatment (χ2 =4.1102, df = 6, 




males showed a dimorphism in their ratio of total progesterone to total 17β-estradiol, with 
females (x = 0.0558) having a higher ratio of progesterone to 17β-estradiol than males (-1.7947). 
Vinclozolin treatment decreased the progesterone to 17β-estradiol ratios in females (x = -0.0842, 
effect size = 249.96% decrease) and increased the ratio in males (x = 0.0614, effect size = 
3,022.96% increase), decreasing the dimorphism. 
 
Progesterone/Corticosterone 
No significant effect was found for the main effect of sex (χ2=0.5548, df=5, p=0.4564) in ratio 
of free progesterone to free corticosterone, thought a significant effect was found for treatment 
(χ2=3.9664, df=4, p=0.04642). No significant effect was found for the interaction between sex 
and treatment (χ2=0.2371, df=6, p=0.6263) for the ratio free progesterone to free corticosterone. 
A significant effect was found for the main effect of sex (Fig. 2.4C, χ2 =5.0594, df = 5, 
p=0.0245) for the ratio of bound progesterone to bound corticosterone, though no significant 
effect was found for treatment (χ2 =0.0585, df = 4, p=0.8089). A significant interaction was 
detected between sex and treatment (Fig. 2.4C, χ2 =8.5364, df = 6, p=0.0035) for the ratio of 
bound progesterone to bound corticosterone. Corn oil control females and males showed a 
dimorphism in their ratio of bound progesterone to bound corticosterone, with females (x = 
0.0760) having a higher ratio of bound progesterone to bound corticosterone than males (-
3.8444). Vinclozolin treatment decreased the bound progesterone to bound corticosterone ratios 
in females (x = -0.2211, effect size = 388.64% decrease) and increased the ratio in males (x = -






No significant effect was found for the main effects of sex (χ2=0.4832, df=4, p=0.4870), or 
treatment (χ2=2.0455, df=6, p=0.1527), or the interaction between sex and treatment (χ2=1.9422, 
df=5, p=0.1634) for the ratio of free testosterone to free estradiol. No significant effect was 
found for the main effects of sex (χ2=0.0252, df=5, p=0.8740), or treatment (χ2=0.0024, df=4, 
p=0.9610) for the ratio of bound testosterone to bound 17β-estradiol. A marginally significant 
interaction was detected between sex and treatment (Fig. 2.5, χ2 =2.9142, df = 6, p=0.0878) for 
the ratio of bound testosterone to bound 17β-estradiol. Corn oil control females and males 
showed a dimorphism in their ratio of bound testosterone to bound 17β-estradiol, with females (x 
= -1.6603) having a lower ratio of bound testosterone to bound 17β-estradiol than males (-
0.1588). Vinclozolin treatment increased the bound testosterone to bound 17β-estradiol ratios in 
females (x = -1.9076, effect size = 114.89% decrease). Vinclozolin decreased the mean bound 
testosterone to bound 17β-estradiol ratios in males (x = -1.0306, effect size = 648.99% decrease). 
This results in reduced dimorphism as Vinclozolin males are indistinguishable from females in 
regard to bound testosterone to 17β-estradiol ratios. No significant effect was found for the main 
effects of sex (χ2=1.0416, df=5, p=0.3075), or treatment (χ2=0.0088, df=4, p=0.9252), or the 
interaction between sex and treatment (χ2=0.7157, df=6, p=0.3976) for the ratio total 
testosterone to total 17β-estradiol.  
 
 
Fetal Liver Steroid Transport Protein Proteomics 
Fetal liver proteomes were analyzed to detect normal dimorphism and changes in steroid 





No sexual dimorphism in steroid binding proteins within liver 
No significant difference was found for alpha-1-fetoprotein between male and female controls 
(p=0.28226). Fold change from male to female was found to be (-0.114244). No significant 
difference was found for corticosteroid binding globulin between males and female controls 
(p=0.913782). Fold change from male to female was (0.0274777). Albumin was also shown to 
have no difference between male and female controls (p=0.670666). Fold change from male to 
female controls was found to be (0.115814).  
 
No significant difference was found for alpha-1-fetoprotein between male and female 
Vinclozolin (p=0.308734). Fold change from male to female was found to be (-0.176465). No 
significant difference was found for corticosteroid binding globulin between males and female 
Vinclozolin (p=0.786258). Fold change from male to female was (-0.09691672). Albumin was 
also shown to have no difference between male and female controls (p=0.762455). Fold change 
from male to female Vinclozolin was found to be (-0.0726662).  
 
Vinclozolin exposure does not change fetal liver steroid binding protein concentrations.  
No significant difference was found for alpha-1-fetoprotein between male control and male 
Vinclozolin (p=0.586694). Fold change from male control to male Vinclozolin was found to be 
(-0.0641747). No significant difference was found for corticosteroid binding globulin between 
male control and male Vinclozolin (p=0.876136). Fold change from male corn oil to male 
Vinclozolin was (-0.0477915). Albumin was also shown to have no difference between male 
control and male Vinclozolin (p=0.769335). Fold change from male control to male Vinclozolin 





No significant difference was found for alpha-1-fetoprotein between female control and female 
Vinclozolin (p=0.427344). Fold change from female control to female Vinclozolin was found to 
be 0.126296. No significant difference was found for corticosteroid binding globulin between 
female control and female Vinclozolin (p=0.806646). Fold change from female to female was 
(0.0766034). Albumin was also shown to have no difference between female control and male 
Vinclozolin (p=0.649299). Fold change from female control to female Vinclozolin was found to 
be 0.107785.  
 
Discussion  
EDCs have been shown to alter free or total steroid concentrations, however, few studies have 
addressed how fractions of steroids change due to EDC exposure (free, bound, total steroid, or 
free/bound ratios) and if these changes alter normal dimorphism. Here we show that fetal plasma 
steroid fractions are dimorphic, and that the dimorphism is reduced by Vinclozolin (Table 2.4). 
Females show a higher concentration of progesterone, a higher ratio of bound progesterone to 
free progesterone, and a higher ratio of bound progesterone than bound metabolites (testosterone, 
17β-estradiol, and corticosterone) and total progesterone to total 17β-estradiol. The opposite is 
the case for males, where males have more free progesterone to bound progesterone and a higher 
ratio of bound metabolites to bound progesterone. These data show a consistent dimorphism in 
the steroid fraction that males and females circulate, with males having more progesterone that 
can be easily metabolized to more potent steroid nuclear receptor signaling molecules and 
greater effect of steroid feedback mechanisms by binding inhibitive nuclear receptors in the 




unable to be converted to downstream steroids, less stimulation of negative feedback, and a 
higher rate of binding steroid binding protein receptors and driving non-genomic steroid 
signaling.  
 
Vinclozolin treatment reduced the ratio of bound progesterone to free progesterone for females 
as well as reduced the bound progesterone to bound steroid metabolite ratio. The exact opposite 
effect was seen in males where free progesterone to bound progesterone concentrations were 
increased as wells as bound progesterone to bound metabolites increased. Vinclozolin shifts 
females to a higher ratio of rate of progesterone metabolism, a higher ratio of progesterone to its 
downstream metabolites, and potentially increases negative feedback mechanisms in females 
while doing the opposite in males. The only ratio that differed from this pattern was for bound 
testosterone to 17β-estradiol (metabolite of testosterone), where both control males and females 
had more bound 17β-estradiol than bound testosterone. Vinclozolin increased the bound 
testosterone to 17β-estradiol ratio in males while decreasing the ratio in females. In all cases, the 
effect of Vinclozolin reduced natural dimorphism by driving masculinizing female and 
feminizing male ratios.  
 
Progesterone, an upstream steroid precursor to corticosterone, testosterone, and estradiol, was 
shown to be dimorphic in the bound fraction (Fig. 2.1A), with corn oil females having higher 
bound concentrations than corn oil males (Fig. 2.1A) and lower free to bound ratios than males 
(Fig. 2.1B). When exposed to Vinclozolin, remarkably males and females lose their dimorphism 
(Fig. 2.1A&B). It is known that Vinclozolin exposure demasculinizes male genitalia, while 




exposed females pups have reduced feminization in progesterone ratios and males have reduced 
masculinization of progesterone ratios. These results reveal two critical breakthroughs in our 
understanding of steroid dependent development. Steroid fractions, not just free concentrations 
of steroids, are normally dimorphic with females showing higher bound steroids and higher 
ratios of less potent precursor molecules to more potent metabolites than males. Strikingly, 
Vinclozolin eliminates this dimorphism. Given that Vinclozolin is an androgen receptor 
antagonist, it is interesting that we did not find statistically significant changes in testosterone 
free, bound, total, or ratios as we would expect that Vinclozolin would reduce inhibition of brain 
negative feedback and propagate testosterone production at the gonadal level. This suggests that 
binding of testosterone to transport proteins may be the chief change with Vinclozolin exposure 
rather than direct effects on brain feedback control.  Other EDCs may have similar effects and 
future work with EDCs need to consider fractions as these effects would be missed if we only 
measured free concentrations. 
 
Furthermore, bound progesterone alone was altered as well as ratios of bound progesterone to its 
downstream metabolites corticosterone, testosterone, and 17β-estradiol. The importance of 
progesterone as a key steroid precursor means that its relationship to its downstream metabolites 
is important. These data show that the ratio of bound progesterone to bound corticosterone (Fig. 
2.4A), bound progesterone to bound testosterone (Fig.2.4B), and bound progesterone to bound 
17β-estradiol (Fig. 2.4C) in corn oil females is higher than those ratios in males. Females 
naturally show a higher ratio of a bound precursor unable to directly bind transcriptional 
mechanisms, but capable of binding transport protein membrane receptors. When exposed to 




bound progesterone to bound metabolite (Fig. 2.4A-C) ratios, whereas males increasing their 
bound progesterone relative to bound metabolites. Lastly, the bound ratio of bound testosterone 
to bound 17β-estradiol is altered by Vinclozolin (Fig. 2.5) with males losing their higher normal 
bound testosterone to bound 17β-estradiol ratio after treatment. These downstream changes 
combined with upstream progesterone changes illustrate the potential for complete shifts in 
steroidogenesis across the steroid pathway. 
 
This study shows that the bound steroid fractions, were altered by Vinclozolin whereas the free 
fractions were not. With a higher fraction of bound progesterone females likely have a higher 
contribution of progesterone-corticosteroid binding globulin complexing to the corticosteroid 
binding globulin receptor resulting in increased non-genomic signaling compared to males. 
Females have higher bound progesterone and a higher ratio of bound to free progesterone (Fig. 
2.1B). This suggests that males have a higher content of progesterone that can be more readily 
taken up into cells and metabolized to downstream steroids or more potent ligands to steroid 
receptors (corticosterone, testosterone, 17β-estradiol, etc.) compared to females. As an example, 
we can consider free to bound ratios of 17β-estradiol (Fig. 2.2), a potent estrogen and 
downstream metabolite of progesterone. Corn oil males have a higher ratio of free to bound 17β-
estradiol than corn oil females and a higher potential for genomic steroid signaling in tissues 
where ER is expressed.  
 
It has recently become more apparent that steroid signaling is beautifully complex and this study 
suggests that measuring single concentrations of free steroids as an endpoint in both directly 




shows that ratios of steroids, not just single free steroids, are dimorphic and exposure to EDCs, 
such as Vinclozolin, can affect both male and female sexual differentiation. Having multiple 
steroids and fractions measured simultaneously provides a wider and more relevant scope of 
steroid signaling. This is especially true considering that steroids are not independently 
transcribed but synthesized in an interconnected metabolic pathway with concentrations of one 
steroid being dependent on another.  
 
Proteomic analysis of steroid transport proteins shows that alterations in free and bound fractions 
occur in the absence of changes in liver steroid transport protein concentrations. Our results did 
not show a significant difference between corn oil and Vinclozolin treatment for liver albumin, 
alpha-1-fetoprotein, or corticosteroid binding globulin, nor were there significant differences in 
these proteins between sexes. This is important as this suggests that abundance of transport 
proteins isn’t be directly affected by Vinclozolin, but rather the interaction between protein and 
the steroid is affected. Vinclozolin, or its metabolites, may competitively bind transport proteins, 
alter their conformation via allosteric binding, or affect protein structure by a posttranslational 
mechanism. Currently, none of these routes have been studied and further work will be necessary 
to distinguish which of the mechanisms may be altered. 
 
There are potential caveats to our finding concerning the lack of significant changes in transport 
protein concentration. First, it has been previously noted that AFP production in the fetal liver 
may be related to fetal hepatocyte cell division, with increases in proliferation correlating with 
increases in AFP mRNA synthesis (Sell et al., 1974). Despite evidence that estrogens increase 




Francavilla et al., 1986; Francavilla et al., 1989),  it may be possible that AFP is not be directly 
linked to steroid nuclear receptor activation, but rather cell cycle mechanisms. Albumin, which is 
a close evolutionary ancestor of AFP and shares conservation in most structure (Pñeiro et al., 
1982), was also shown to have a positive correlation between mRNA concentration and 
proliferation in mature hepatocytes (Hannah et al., 1980) and may have similar independence to 
steroid receptor mechanisms as AFP. It is possible that CBG and other transport proteins may 
have a similar cell division-based regulation during fetal development rather than steroidal 
regulated proliferation.  
 
Second given the sheer abundance of these proteins, it is possible that change in protein 
concentration, though small, may be biologically important. Third and final, is that change (or 
lack thereof) in concentration of transport proteins in the liver tissue may not be representative of 
concentrations in the plasma, where transport proteins functionally regulate steroids. Due to the 
low volume of plasma available in our pups, circulating transport protein concentrations were 
impossible to retrieve. Furthermore, capturing liver tissue and interstitial fluid protein 
concentrations captures newly produced, circulating, and degrading transport proteins in the 
liver. Further study of protein expression may provide a more direct measurement of EDC 
effects on transport protein synthesis. 
 
Conclusions 
Free and bound fractions of fetal steroids are normally dimorphic with females having higher 
bound to free ratios and higher precursor steroid progesterone to metabolites ratios than males. 




development and changes to ratio of progesterone to its metabolites and in a sex-dependent way. 
Decreasing the ratio in females and increasing the ratio in females. These EDC driven alterations 
are sex-dependent and lead to a reduced dimorphic profile of steroids and steroid fractions that 
influence reduced dimorphic phenotypes seen in many common congenital diseases (i.g 
hypospadias (Amato and McCoy, 2016)). Most evidence of endocrine disruption focuses on 
single steroid to single phenotype changes without regard to their free or bound fraction or 
relation to other steroid metabolites. This perspective places individual steroids into solitary 
vacuums and neglects the complex interactions of steroids that drive dimorphic development. 
This study shows that steroid fractions, particularly the oft ignored bound fraction, and ratios to 
each other are naturally dimorphic in the fetus and thus are relevant to sex-dependent 
development, can be altered by EDCs, and steroid fractions must be considered when evaluating 
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CHAPTER 3: THESIS CONCLUCIONS AND IMPACTS 
 
Years of research have shown the importance that steroid hormones contribute to sexual 
differentiation and healthy dimorphisms. Paralleled to these endeavors, are decades worth of 
studies that show roles that steroid transport proteins play in regulating steroid activity by 
separating steroids into free and bound fractions. Despite the wide range of academic attention 
that both steroids and their transports have garnered, few studies have sought to synthesis these 
fields of work into a more descriptive, albeit complex, model of steroid function and disruption 
(Fig 1.1). Furthermore, understanding of this natural complexity represents the very solution for 
combating the ever-present threat of endocrine disruption. Here, presented in this Thesis, I have 
addressed four major aspects in the disruption of steroid signaling and the roles that steroid 
transport proteins play in this disruption. 
 
First, presented in chapter I, I reviewed the past and current literature of the major steroid 
transport proteins, their regulation, and exposure to common environmental contaminants, and 
show that steroid transport proteins have the clear potential to be altered by a diverse array of 
endocrine disruptors, whether in concentration or function. These alterations were found to occur 
at the level of transport protein expression, the interface of transport protein and its cognate 
steroids, by modulating the structure of the protein, and/or by interfering with transport protein 
binding their receptors.  
Second, using LCMSMS analysis of fetal plasma, I show that there are natural dimorphisms in 
fractions of free and bound steroids, with females generally having a higher fraction of bound 





their male counterparts. This work is critical in showing that dimorphisms do exist in steroid 
fraction between male and females during early stages of sexual differentiation, and these 
differences in free and bound steroids may drive the mechanisms that divert males and females 
from a bipotential state. Most studies measuring steroid concentrations as an endpoint in 
endocrine disruption report only free steroids, though on occasion sum have provided total 
steroid fractions. This study provides the evidence to justify measuring free and bound steroids 
for future study as the dimorphism in steroid physiology shown here would have been impossible 
without consideration of steroid fractions. Future work should aim to manipulate concentrations 
of free and bound fractions of steroids to measure phenotypic endpoints dimorphism both 
anatomically and physiologically. One example, would be to directly alter free progesterone by 
increasing or decreasing its concentration. Doing so will likely alter available substrate for 
creating downstream steroid metabolites and alter their concentrations and may have 
considerable impacts on dimorphic development.  
The third major contribution of this thesis, was in showing that a model EDC and antiandrogen 
can indeed alter steroid fractions. As noted in the review found in chapter one, there has been 
evidence of changes in transport proteins due to therapeutic and synthetic steroids, however 
studies of antiandrogen effects were lacking. What is notable in this study is that we found 
changes in steroid fractions directly in the form of altered fraction ratios with antiandrogen 
exposure and that these ratios where not based on changes of transport protein concentration of 
the liver. This suggests some form of disruption in steroid binding to the transport protein. 
Whether Vinclozolin is competitively binding transport proteins, displacing native steroids from 




should further explore the binding kinetics and protein interactions of these transports and 
Vinclozolin.  
The last major finding from this research, is that male and female fetuses responded to 
Vinclozolin differently, in terms of their steroid fractions.  Males exposed to Vinclozolin 
exhibited a feminization of fraction while, females exhibited the opposite effect with a non-
statistically significant, but clear and recurring trend toward masculinization. These changes 
show the importance in measuring steroid fractions as many common human reproductive 
diseases such as hypospadias and poly cystic ovarian syndrome as the results of reduced 
dimorphism in steroid physiology. EDC driven effects of altered steroid fractions may be culprits 
for the large increased diagnoses seen in such diseases. Interestingly, no dimorphism in the post 
translational modification, general moiety, or concentrations of transport proteins has been 
shown, though little study currently exists. Further biochemical analysis of male and female 
protein and maintenance of the protein post production would help solve this gap in knowledge.  
It is has become apparent over the past several decades that humanity’s successes in production 
have led to a demise in the efficacy of our world’s biological development. With an ever-
increasing list of disruptive chemicals that alter the physiology and anatomy of both humans and 
wildlife, describing the process by which EDCs affect development is paramount. In culmination 
of its works and words, this study has moved our knowledge of steroid transport physiology and 
disruption one step forward, with the hope that humans and wildlife will be one step closer to a 




Table 2.1. LC-MS Method Parameters for Positive Mode 
Parameter Unit Parameter Unit 
LC flow 
pressure range 












15.0 µL/s GS1 20 psi  


























Time (s) duration (s) Flow (nl/min) % solvent B 
2 2 300 0 
242 240 300 40 
244 2 300 80 
254 10 300 80 
255 1 300 0 
256 1 300 0 
270 14 300 0 
  














Bound Progesterone Lower Higher Increase Decrease 
Free/Bound Progesterone Higher Lower Decrease Increase 
Free/Bound 17β-estradiol Higher Lower Increase Decrease 
Bound Progesterone/Bound 
Corticosterone Lower Higher Increase Decrease 
Bound Progesterone/Bound 
Testosterone Lower Higher Increase Decrease 
Bound Progesterone/Bound 17β-
estradiol Lower Higher Increase Decrease 
Total Progesterone/Total 17β-estradiol Lower Higher Increase Decrease 
Bound Testosterone/Bound 17β-























Figure 2.1: No detection of free steroid carryover into bound extraction. X-axis is 
molecule retention time in minutes, Y-axis is signal intensity represented as molecules 
signal counts per second (cps). (A) Chromatogram of free fraction corn oil female plasma 
injected with progesterone-D8 (Fragment peaks of 324.445/113.000 Da, expected retention 
time of 9.98 min) external standard. Peak reading shows relative intensity of  for 
progesterone-D8 as 970 cps. Note that the y-axis scale spans 0 cps to 1000 cps. (B) 
Chromatogram of bound fraction in the same corn oil female plasma after free steroids and 
spiked porgesterone-D8 were extracted. No peak is seen at the expected retention time of 
9.98 min for progesterone-D8 (324.445/113.000 Da), showing that there is no carryover of 






Figure 2.2: Progesterone fractions in males and females when exposed to Vinclozolin. (A) Log 
concentration of bound progesterone. (B) Log ratio of free-to-bound progesterone. Squares are 
corn oil control and triangles are Vinclozolin. A log ratio value of 0 shows 1:1 ratio. All positive 
values have a higher free than bound progesterone, all negative values show higher bound than 





  Figure 2.3: 17β-estradiol ratio in males and females when exposed to Vinclozolin. Log ratio of 
free-to-bound 17β-estradiol concentrations. Squares are corn oil control and triangles are 
Vinclozolin. A log ratio value of 0 shows 1:1 ratio. All positive values have a higher free than 






Figure 2.4: Bound progesterone to bound steroid metabolite ratios in males and females when exposed to 
Vinclozolin. (A) Log ratio of bound progesterone/corticosterone. B) Log ratio of bound 
progesterone/testosterone. (C) Log ratio of bound progesterone/17β-estradiol. Squares are corn oil control 
and triangles are Vinclozolin. A log ratio value of 0 shows 1:1 ratio. All positive values have a higher 







  Figure 2.5: Bound testosterone to bound 17β-estradiol log ratio in males and females when 
exposed to Vinclozolin. Squares are corn oil control and triangles are Vinclozolin. A log ratio 
value of 0 shows 1:1 ratio. All positive values have a higher bound testosterone than bound 17β-
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